Takeda's Actos sales suffer on safety questions; Valeant sales hike helps turn to profit;

@FiercePharma:  GSK settles U.S. investigation for $3B. News | Follow @FiercePharma

> Takeda Pharmaceutical posted weaker Q3 sales as safety questions hurt its diabetes drug Actos; the Japanese drugmaker also cut its full-year profit forecast on Nycomed buyout costs and the strong yen. News

> Valeant Pharmaceuticals posted third-quarter revenue of $601 million, a 40% increase year-over-year including recent acquisitions, and an organic growth rate of 15%. Valeant release

> Jordan's Hikma Pharmaceuticals saw increased sales of branded drugs as turmoil in its Middle Eastern markets eased. Item

> One of Taro Pharmaceutical's independent shareholders lambasted a minority-buyout offer from Sun Pharmaceutical Industries and called for a "truly independent" board committee to evaluate it. Release

> Brazil Pharma agreed to pay $260 million for the Big Ben chain of pharmacies, with 146 stores concentrated in the country's north and northeast. Story

> Aoxing Pharmaceuticals' Chinese subsidiary won government funding for improvements to its manufacturing facility in Hebei Province. Report

> Vanda Pharmaceuticals posted $8 million in revenue for the third quarter, fueled by royalties on its Fanapt antipsychotic drug, which saw a 10% increase in prescriptions year over year. Article

> Germany's Grünenthal tapped Jan-Uwe Claas to head up its U.K. subsidiary. Report

Biotech News

@FierceBiotech: Gates' legendary discipline transforms vaccine effort. Item | Follow @FierceBiotech 

@JohnCFierce: Inhibitex shares have more than doubled since their release discussing their interferon-free approach to hep C. Story | Follow @JohnCFierce

@RyanMFierce:  Looks like Pfizer won't be axing as many R&D workers at Sandwich UK site as we thought. Retaining 650 workers. News | Follow @RyanMFierce

> FDA gives new shot to Vivus obesity drug. News

And Finally... Can't sleep? Blame these neurons. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.